Overview:
The management of advanced melanoma continues to evolve rapidly, with oncolytic immunotherapies emerging as pivotal treatment options. Despite these advancements, challenges with integrating these therapies into multidisciplinary clinical practice remain at the forefront.
This live program will bring together multidisciplinary experts to discuss the importance of collaboration between interventional radiologists and medical oncologists, and will feature real-world, practical case-based discussions to improve procedural workflows, optimize treatment sequencing, and foster efficient communication protocols. A focus on understanding resistance to first-line therapies and exploring advanced therapeutic strategies, such as oncolytic viruses and combination immunotherapies, will help practicing clinicians navigate the complexities of advanced melanoma treatment. The interactive tumor board discussions will provide participants with actionable strategies for lesion prioritization, intralesional injection techniques, and insight into evidence-based decision-making to help inform treatment selection. By incorporating the latest clinical trial data, the program will offer insights into the efficacy, safety, and real-world application of these innovative therapies to advance personalized care and optimize outcomes for patients with advanced melanoma.
Learning Objectives:
Upon completion of this activity, participants will be able to:
- Analyze clinical and safety evidence for second-line therapies, including oncolytic viruses, TILs, and combination immunotherapies, for patients with melanoma after progression on PD-1 inhibitors.
- Identify imaging and procedural strategies for effective lesion prioritization during oncolytic immunotherapy.
- Evaluate the current and evolving impact of oncolytic immunotherapy on interventional oncology practices in melanoma care.
- Summarize the mechanisms, administration techniques, and clinical benefits of oncolytic viruses and combination therapies for melanoma.
Yana Najjar, MD
Associate Professor of Medicine
Director, Clinical and Translational Research Center
UPMC Hillman Cancer Center
Pittsburgh, PA
Rahul A. Sheth, MD, FSIR
Associate Professor, Department of Interventional Radiology, Division of Diagnostic Imaging
The University of Texas MD Anderson Cancer Center
Houston, TX
Douglas Johnson, MD, MSCI
Co-Leader, Translational Research and Interventional Oncology Research Program
Professor of Medicine (Hematology/Oncology)
Clinical Director, Melanoma
Vanderbilt-Ingram Medical Center
Nashville, TN
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM). Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.